Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00842556 · ClinicalTrials.gov registry record · Phase 1
Pharmacokinetic Drug Interaction Study of Dapagliflozin and Glimepiride or Sitagliptin in Healthy Subjects
A Phase 1 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT00842556 is a Phase 1 study that has completed, run by AstraZeneca. The registered enrollment target is 18 participants.
The verdict
NCT00842556, a Phase 1 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
To assess the effect of glimepiride on the PK of dapagliflozin and the effect of dapagliflozin on the PK of glimepiride, when co-administered in healthy subjects (Phase A) and to assess the effect of sitagliptin on the PK of dapagliflozin and the effect of dapagliflozin on the PK of sitagliptin, when co-administered in healthy subjects (Phase B)
Interventions
- DRUG Sitagliptin
- DRUG Dapagliflozin
- DRUG Glimepiride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2009-03 |
| Est. Completion | 2009-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00842556
The ClinicalTrials.gov registry entry for NCT00842556 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Sitagliptin is the first listed.
NCT00842556 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00842556 about?
NCT00842556 is a clinical study titled "Pharmacokinetic Drug Interaction Study of Dapagliflozin and Glimepiride or Sitagliptin in Healthy Subjects". To assess the effect of glimepiride on the PK of dapagliflozin and the effect of dapagliflozin on the PK of glimepiride, when co-administered in healthy subjects (Phase A) and to assess the effect of sitagliptin on the PK of dapagliflozin and the effect of dapagliflozin on the PK of sitagliptin, whe...
What is the current status of trial NCT00842556?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2009-03. Estimated completion is 2009-05.
What interventions are being tested in trial NCT00842556?
The interventions under investigation include: Sitagliptin (DRUG), Dapagliflozin (DRUG), Glimepiride (DRUG).
Who is sponsoring clinical trial NCT00842556?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.